Evidence map›Paper›PMID 38094565›Full record

ArticleCureus2023

Optimal Bladder Volume for Hypofractionated Proton Therapy in Each Localized Prostate Cancer Risk Group.

Yuki Narita, Takahiro Kato, Yojiro Ishikawa, Kimihiro Takemasa, Hisashi Yamaguchi, Masao Murakami

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Yuki NaritaDepartment of Radiation Physics and Technology, Southern Tohoku Proton Therapy Center, Koriyama, JPN.
Takahiro KatoSchool of Health Sciences, Fukushima Medical University, Fukushima, JPN.
Yojiro IshikawaDepartment of Radiation Oncology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, JPN.
Kimihiro TakemasaDepartment of Radiation Physics and Technology, Southern Tohoku Proton Therapy Center, Koriyama, JPN.
Hisashi YamaguchiDepartment of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, JPN.
Masao MurakamiDepartment of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, JPN.
Southern Tohoku General Hospital · JPFukushima Medical University · JPProton (Malaysia) · MYTohoku Medical and Pharmaceutical University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background This study aimed to determine the optimal bladder volume (BV) for hypofractionated proton therapy in prostate cancer (PC). Materials and methods Two hundred patients with PC were enrolled in this study and classified into low-, intermediate-, and high-risk groups. Treatment planning was performed by assuming a hypofractionated schedule of 63 Gy (relative biological effectiveness) in 21 fractions. The dose indices of the bladder (V

Indexed as

bladder volumehypofractionated rtprostate cancerproton therapyradiotherapy (rt)

Identifiers

PMID38094565
PMCPMC10716574
OpenAlexW4388636108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.